
 <p style="text-align: center;"><b>Oregon Health &amp; Science University Hospital and Clinics Provider's Orders</b></p> <p style="font-size: small;">PO9031</p>  <p style="text-align: center;">ADULT AMBULATORY INFUSION ORDER <b>Mepolizumab (NUCALA) Subcutaneous Injection</b></p> <p style="text-align: center; font-size: x-small;">Page 1 of 2</p>	<p>ACCOUNT NO. _____</p> <p>MED. REC. NO. _____</p> <p>NAME _____</p> <p>BIRTHDATE _____</p> <p style="text-align: right; font-size: x-small;"><i>Patient Identification</i></p>
<b>ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE</b>	

**Weight:** \_\_\_\_\_ kg      **Height:** \_\_\_\_\_ cm

**Allergies:** \_\_\_\_\_

**Diagnosis Code:** \_\_\_\_\_

**Treatment Start Date:** \_\_\_\_\_      **Patient to follow up with provider on date:** \_\_\_\_\_

**\*\*This plan will expire after 365 days at which time a new order will need to be placed\*\***

**GUIDELINES FOR ORDERING**

1. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with mepolizumab. Decrease corticosteroids gradually, if appropriate.
2. Herpes zoster infections have occurred in patients receiving mepolizumab. Consider varicella vaccination if medically appropriate prior to starting therapy with mepolizumab.
3. Treat patients with pre-existing helminth infections before therapy with mepolizumab. If patients become infected while receiving treatment with mepolizumab and do not respond to anti-helminth treatment, discontinue mepolizumab until parasitic infection resolves.

**MEDICATIONS:**

mepolizumab (NUCALA) injection, subcutaneous, ONCE

**Asthma:**

100 mg

**Eosinophilic granulomatosis with polyangitis (treatment) Dose:**

300 mg (administer as THREE separate 100 mg injections at a distance 5 cm or more apart)

**Interval:**

Every 4 weeks

**NURSING ORDERS:**

1. Administer subcutaneously into the upper arm, thigh, or abdomen. Do not inject into skin that is tender, bruised, red, or hard.
2. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declothing (alteplase), and/or dressing changes.
3. Observe patient for hypersensitivity reactions, including anaphylaxis, for 30 minutes after administration.



Oregon Health & Science University  
Hospital and Clinics Provider's Orders

OHSU  
Health

ADULT AMBULATORY INFUSION ORDER

**Mepolizumab (NUCALA)  
Subcutaneous Injection**

Page 2 of 2

ACCOUNT NO.  
MED. REC. NO.  
NAME  
BIRTHDATE

Patient Identification

**ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE**

**HYPERSENSITIVITY MEDICATIONS:**

1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydramine (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

**By signing below, I represent the following:**

I am responsible for the care of the patient (*who is identified at the top of this form*);

I hold an active, unrestricted license to practice medicine in:  Oregon  \_\_\_\_\_ (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

**My physician license Number is # \_\_\_\_\_ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION);** and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

**Provider signature:** \_\_\_\_\_ **Date/Time:** \_\_\_\_\_

**Printed Name:** \_\_\_\_\_ **Phone:** \_\_\_\_\_ **Fax:** \_\_\_\_\_

**Please check the appropriate box for the patient's preferred clinic location:**

**Hillsboro Medical Center**  
Infusion Services  
364 SE 8th Ave, Medical Plaza Suite 108B  
Hillsboro, OR 97123  
Phone number: (503) 681-4124  
Fax number: (503) 681-4120

**Adventist Health Portland**  
Infusion Services  
10123 SE Market St  
Portland, OR 97216  
Phone number: (503) 261-6631  
Fax number: (503) 261-6756

**Mid-Columbia Medical Center**  
Celilo Cancer Center  
1800 E 19th St  
The Dalles, OR 97058  
Phone number: (541) 296-7585  
Fax number: (541) 296-7610